|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LRRC37A3 |
Gene summary for LRRC37A3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LRRC37A3 | Gene ID | 374819 |
| Gene name | leucine rich repeat containing 37 member A3 | |
| Gene Alias | LRRC37 | |
| Cytomap | 17q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | J3QTJ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 374819 | LRRC37A3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.74e-02 | -2.30e-01 | 0.0155 |
| 374819 | LRRC37A3 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.30e-02 | 3.55e-01 | -0.1954 |
| 374819 | LRRC37A3 | A015-C-203 | Human | Colorectum | FAP | 2.56e-10 | -1.04e-01 | -0.1294 |
| 374819 | LRRC37A3 | A002-C-201 | Human | Colorectum | FAP | 7.77e-05 | -8.51e-02 | 0.0324 |
| 374819 | LRRC37A3 | A001-C-119 | Human | Colorectum | FAP | 1.98e-02 | 8.31e-02 | -0.1557 |
| 374819 | LRRC37A3 | A001-C-108 | Human | Colorectum | FAP | 2.39e-05 | 4.22e-02 | -0.0272 |
| 374819 | LRRC37A3 | A002-C-021 | Human | Colorectum | FAP | 4.42e-02 | 3.59e-01 | 0.1171 |
| 374819 | LRRC37A3 | A002-C-205 | Human | Colorectum | FAP | 4.98e-09 | -6.85e-02 | -0.1236 |
| 374819 | LRRC37A3 | A015-C-006 | Human | Colorectum | FAP | 7.22e-07 | -1.52e-01 | -0.0994 |
| 374819 | LRRC37A3 | A002-C-114 | Human | Colorectum | FAP | 7.62e-06 | -5.59e-02 | -0.1561 |
| 374819 | LRRC37A3 | A015-C-104 | Human | Colorectum | FAP | 8.37e-11 | -6.85e-02 | -0.1899 |
| 374819 | LRRC37A3 | A015-C-202 | Human | Colorectum | FAP | 4.84e-07 | 4.47e-01 | -0.0849 |
| 374819 | LRRC37A3 | A001-C-014 | Human | Colorectum | FAP | 1.08e-03 | -2.46e-02 | 0.0135 |
| 374819 | LRRC37A3 | A002-C-016 | Human | Colorectum | FAP | 1.13e-07 | -4.71e-02 | 0.0521 |
| 374819 | LRRC37A3 | A015-C-002 | Human | Colorectum | FAP | 8.49e-04 | -2.09e-01 | -0.0763 |
| 374819 | LRRC37A3 | A002-C-116 | Human | Colorectum | FAP | 4.22e-13 | -1.38e-01 | -0.0452 |
| 374819 | LRRC37A3 | A014-C-008 | Human | Colorectum | FAP | 9.35e-05 | 1.63e-02 | -0.191 |
| 374819 | LRRC37A3 | A018-E-020 | Human | Colorectum | FAP | 1.55e-08 | 8.87e-02 | -0.2034 |
| 374819 | LRRC37A3 | F034 | Human | Colorectum | FAP | 4.54e-08 | 7.69e-02 | -0.0665 |
| 374819 | LRRC37A3 | CRC-3-11773 | Human | Colorectum | CRC | 2.03e-02 | 2.08e-01 | 0.2564 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LRRC37A3 | SNV | Missense_Mutation | c.3638A>G | p.Glu1213Gly | p.E1213G | O60309 | protein_coding | deleterious(0.03) | probably_damaging(0.932) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| LRRC37A3 | SNV | Missense_Mutation | c.4094T>C | p.Leu1365Pro | p.L1365P | O60309 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LRRC37A3 | SNV | Missense_Mutation | c.3278C>T | p.Ser1093Leu | p.S1093L | O60309 | protein_coding | deleterious(0.01) | probably_damaging(0.942) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| LRRC37A3 | SNV | Missense_Mutation | c.4270N>C | p.Glu1424Gln | p.E1424Q | O60309 | protein_coding | tolerated(0.11) | probably_damaging(0.932) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| LRRC37A3 | SNV | Missense_Mutation | novel | c.4150N>C | p.Glu1384Gln | p.E1384Q | O60309 | protein_coding | deleterious(0.01) | benign(0.055) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LRRC37A3 | SNV | Missense_Mutation | novel | c.3450N>G | p.Ser1150Arg | p.S1150R | O60309 | protein_coding | deleterious(0.01) | probably_damaging(0.944) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LRRC37A3 | SNV | Missense_Mutation | c.4655N>A | p.Ile1552Asn | p.I1552N | O60309 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LRRC37A3 | SNV | Missense_Mutation | c.4415N>T | p.Gln1472Leu | p.Q1472L | O60309 | protein_coding | deleterious(0.02) | possibly_damaging(0.838) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LRRC37A3 | SNV | Missense_Mutation | c.62C>T | p.Pro21Leu | p.P21L | O60309 | protein_coding | tolerated(0.06) | benign(0.001) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LRRC37A3 | insertion | Nonsense_Mutation | novel | c.4741_4742insCTAGTCTCGCGACGTTTTAATTAGAATTTTAGAATT | p.Lys1581delinsThrSerLeuAlaThrPheTerLeuGluPheTerAsnTer | p.K1581delinsTSLATF*LEF*N* | O60309 | protein_coding | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |